ArticleBMC pediatrics2026
Refractory Mycobacterium fortuitum skin and soft tissue infection following dog bite in a pediatric patient: a case report.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycobacterium fortuitum (M. fortuitum), a rapidly growing nontuberculous mycobacterium (NTM), is an emerging pathogen in trauma-associated skin and soft tissue infections (SSTIs). Pediatric NTM infections are rare and often misdiagnosed due to nonspecific clinical manifestations mimicking those of pyogenic bacterial infections. We report the first pediatric case of refractory M. fortuitum SSTIs following a dog bite in an 8-year-old child, highlighting diagnostic and management challenges. CASE PRESENTATION: An 8-year-old child presented with SSTIs on the anteromedial right thigh following a dog bite, which remained refractory to a 2-week course of empiric β-lactam therapy. Histopathology revealed nodular granulomatous inflammation with epithelioid cells and purulent necrosis, and acid-fast bacilli were identified via Ziehl-Neelsen staining. Targeted next-generation sequencing (tNGS) rapidly identified M. fortuitum within 48 h, with confirmation by automated liquid culture (7-day growth) and targeted PCR. A multidisciplinary approach integrating broth microdilution-guided combination therapy (amikacin 15 mg/kg IV q48h, linezolid 10 mg/kg PO q12h, and doxycycline 3 mg/kg PO q12h) with weekly or biweekly surgical debridement achieved complete resolution of the cutaneous lesions. No relapse was noted during 6 months of follow-up, with regular clinical and laboratory evaluations.
conclusionsThis case underscores three critical findings: (1) NTM infections warrant inclusion in the differential diagnosis of animal bite wounds refractory to β-lactams; (2) tNGS facilitates rapid rare pathogen identification, enabling target-directed therapy within 48 h; (3) The multidisciplinary team is imperative to coordinate combined antimicrobial and surgical interventions. Enhanced awareness of the zoonotic potential of NTM is recommended for bite wound management, particularly in pediatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.